Cellectis S.A.: Clinical Trials

2 trials sponsored by Cellectis S.A., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Recruiting 1
Phase 22Active not recruiting 1, Recruiting 1

Follow Cellectis S.A.: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
UCART20x22, CLLS52 - B-cell Non-Hodgkin Lymphoma (B-NHL)
Phase 1 / Phase 2RecruitingCellectis S.A.802022-11-012025-08-24
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
UCART22, CLLS52 - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingCellectis S.A.452019-10-142026-11-09

Conditions studied

Recurrence (2)  ·  Burkitt Lymphoma (1)  ·  Lymphoma, B-Cell (1)

Interventions

Alemtuzumab (2)

Countries

France (2)  ·  United States (2)  ·  Spain (1)

Top investigators

Jeremy Abramson, MD (1)  ·  Nitin Jain, MD (1)